Moderna Stock Drops 36% Despite Strong Profits - Is It a Buying Opportunity or Growth Slowdown?

Moderna's share price has declined 36% over the last 3 months despite decent financials, presenting a potential buying opportunity.

Return on equity (ROE) measures how efficiently Moderna generates profits from shareholders' investments. Their ROE is 7.1%.

Higher ROE and profit retention typically indicates greater growth potential. Moderna's earnings grew 60% over 5 years despite low ROE.

Moderna's earnings growth exceeds the industry average of 22%, suggesting positive company-specific factors like high reinvestment.

Analysts forecast Moderna's earnings will shrink going forward, so future growth prospects appear limited.